Found: 40
Select item for more details and to access through your institution.
Clinical trial: An open‐label, randomised trial of different re‐start strategies after treatment withdrawal in HBeAg negative chronic hepatitis B.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2024, v. 60, n. 4, p. 434, doi. 10.1111/apt.18147
- By:
- Publication type:
- Article
Type I Interferon Autoantibodies Correlate With Cellular Immune Alterations in Severe COVID-19.
- Published in:
- Journal of Infectious Diseases, 2024, v. 230, n. 2, p. e318, doi. 10.1093/infdis/jiae036
- By:
- Publication type:
- Article
Liver stiffness predicts progression to liver-related events in patients with chronic liver disease - A cohort study of 14414 patients.
- Published in:
- Liver International, 2024, v. 44, n. 7, p. 1689, doi. 10.1111/liv.15919
- By:
- Publication type:
- Article
Liver stiffness measurement as a noninvasive method for the diagnosis of liver cirrhosis in patients with chronic hepatitis D virus infection.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2024, v. 59, n. 6, p. 752, doi. 10.1111/apt.17878
- By:
- Publication type:
- Article
The cascade of care for patients with chronic hepatitis delta in Southern Stockholm, Sweden for the past 30 years.
- Published in:
- Liver International, 2024, v. 44, n. 1, p. 228, doi. 10.1111/liv.15770
- By:
- Publication type:
- Article
Impact of the gut microbiome on immunological responses to COVID-19 vaccination in healthy controls and people living with HIV.
- Published in:
- NPJ Biofilms & Microbiomes, 2023, v. 9, n. 1, p. 1, doi. 10.1038/s41522-023-00461-w
- By:
- Publication type:
- Article
SARS-CoV-2 vaccination enhances the effector qualities of spike-specific T cells induced by COVID-19.
- Published in:
- Science Immunology, 2023, v. 8, n. 90, p. 1, doi. 10.1126/sciimmunol.adh0687
- By:
- Publication type:
- Article
Natural history of untreated HDV patients: Always a progressive disease?
- Published in:
- Liver International, 2023, v. 43, n. 1, p. 5, doi. 10.1111/liv.15467
- By:
- Publication type:
- Article
SARS-CoV-2 Antibodies in Commercial Immunoglobulin Products Show Markedly Reduced Cross-reactivities Against Omicron Variants.
- Published in:
- Journal of Clinical Immunology, 2023, v. 43, n. 6, p. 1075, doi. 10.1007/s10875-023-01486-8
- By:
- Publication type:
- Article
IMPACT OF GUT MICROBIOTA ON IMMUNOGENICITY TO COVID-19 VACCINES IN PLWH.
- Published in:
- Topics in Antiviral Medicine, 2023, v. 31, n. 2, p. 147
- By:
- Publication type:
- Article
Correction to: Persisting Salivary IgG Against SARS-CoV-2 at 9 Months After Mild COVID-19: A Complementary Approach to Population Surveys.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
Persistence of salivary antibody responses after COVID-19 vaccination is associated with oral microbiome variation in both healthy and people living with HIV.
- Published in:
- Frontiers in Immunology, 2023, v. 13, p. 01, doi. 10.3389/fimmu.2022.1079995
- By:
- Publication type:
- Article
Monitoring the progress towards the elimination of hepatitis B and C in Sweden: estimation of core indicators for 2015 and 2018.
- Published in:
- BMC Infectious Diseases, 2022, v. 22, n. 1, p. 1, doi. 10.1186/s12879-022-07886-2
- By:
- Publication type:
- Article
Monitoring the progress towards the elimination of hepatitis B and C in Sweden: estimation of core indicators for 2015 and 2018.
- Published in:
- 2022
- By:
- Publication type:
- journal article
A universal SARS‐CoV DNA vaccine inducing highly cross‐reactive neutralizing antibodies and T cells.
- Published in:
- EMBO Molecular Medicine, 2022, v. 14, n. 10, p. 1, doi. 10.15252/emmm.202215821
- By:
- Publication type:
- Article
Neutralizing SARS-CoV-2 Antibodies in Commercial Immunoglobulin Products Give Patients with X-Linked Agammaglobulinemia Limited Passive Immunity to the Omicron Variant.
- Published in:
- Journal of Clinical Immunology, 2022, v. 42, n. 6, p. 1130, doi. 10.1007/s10875-022-01283-9
- By:
- Publication type:
- Article
Elevated CD21<sup>low</sup> B Cell Frequency Is a Marker of Poor Immunity to Pfizer-BioNTech BNT162b2 mRNA Vaccine Against SARS-CoV-2 in Patients with Common Variable Immunodeficiency.
- Published in:
- Journal of Clinical Immunology, 2022, v. 42, n. 4, p. 716, doi. 10.1007/s10875-022-01244-2
- By:
- Publication type:
- Article
Probabilistic classification of anti‐SARS‐CoV‐2 antibody responses improves seroprevalence estimates.
- Published in:
- Clinical & Translational Immunology, 2022, v. 11, n. 3, p. 1, doi. 10.1002/cti2.1379
- By:
- Publication type:
- Article
Risk of hepatocellular carcinoma in hepatitis B and D virus co‐infected patients: A systematic review and meta‐analysis of longitudinal studies.
- Published in:
- Journal of Viral Hepatitis, 2021, v. 28, n. 10, p. 1431, doi. 10.1111/jvh.13577
- By:
- Publication type:
- Article
Hepatitis C elimination in Sweden: Progress, challenges and opportunities for growth in the time of COVID‐19.
- Published in:
- Liver International, 2021, v. 41, n. 9, p. 2024, doi. 10.1111/liv.14978
- By:
- Publication type:
- Article
Persisting Salivary IgG Against SARS-CoV-2 at 9 Months After Mild COVID-19: A Complementary Approach to Population Surveys.
- Published in:
- 2021
- By:
- Publication type:
- journal article
SARS‐CoV‐2‐specific humoral and cellular immunity persists through 9 months irrespective of COVID‐19 severity at hospitalisation.
- Published in:
- Clinical & Translational Immunology, 2021, v. 10, n. 7, p. 1, doi. 10.1002/cti2.1306
- By:
- Publication type:
- Article
Mortality among amphetamine users with hepatitis C virus infection: A nationwide study.
- Published in:
- PLoS ONE, 2021, v. 16, n. 6, p. 1, doi. 10.1371/journal.pone.0253710
- By:
- Publication type:
- Article
Innate lymphoid cell composition associates with COVID‐19 disease severity.
- Published in:
- Clinical & Translational Immunology, 2020, v. 9, n. 12, p. 1, doi. 10.1002/cti2.1224
- By:
- Publication type:
- Article
MAIT cell activation and dynamics associated with COVID-19 disease severity.
- Published in:
- Science Immunology, 2020, v. 5, n. 51, p. 1, doi. 10.1126/sciimmunol.abe1670
- By:
- Publication type:
- Article
Frequent loss to follow‐up after diagnosis of hepatitis C virus infection: A barrier towards the elimination of hepatitis C virus.
- Published in:
- Liver International, 2020, v. 40, n. 8, p. 1832, doi. 10.1111/liv.14469
- By:
- Publication type:
- Article
Natural killer cell immunotypes related to COVID-19 disease severity.
- Published in:
- Science Immunology, 2020, v. 5, n. 50, p. 1, doi. 10.1126/sciimmunol.abd6832
- By:
- Publication type:
- Article
Chronic Viral Liver Diseases: Approaching the Liver Using T Cell Receptor-Mediated Gene Technologies.
- Published in:
- Cells (2073-4409), 2020, v. 9, n. 6, p. 1471, doi. 10.3390/cells9061471
- By:
- Publication type:
- Article
Plasma FABP4 is associated with liver disease recovery during treatment-induced clearance of chronic HCV infection.
- Published in:
- Scientific Reports, 2020, v. 10, n. 1, p. 1, doi. 10.1038/s41598-020-58768-z
- By:
- Publication type:
- Article
The Consensus Hepatitis C Cascade of Care: Standardized Reporting to Monitor Progress Toward Elimination.
- Published in:
- Clinical Infectious Diseases, 2019, v. 69, n. 12, p. 2218, doi. 10.1093/cid/ciz714
- By:
- Publication type:
- Article
Prevalence of Viremic hepatitis C, hepatitis B, and HIV infection, and vaccination status among prisoners in Stockholm County.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Lipophilic Statins and Risk for Hepatocellular Carcinoma and Death in Patients With Chronic Viral Hepatitis: Results From a Nationwide Swedish Population.
- Published in:
- Annals of Internal Medicine, 2019, v. 171, n. 5, p. 318, doi. 10.7326/M18-2753
- By:
- Publication type:
- Article
Lipophilic Statins and Risk for Hepatocellular Carcinoma and Death in Patients With Chronic Viral Hepatitis: Results From a Nationwide Swedish Population.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Tissue‐resident MAIT cell populations in human oral mucosa exhibit an activated profile and produce IL‐17.
- Published in:
- European Journal of Immunology, 2019, v. 49, n. 1, p. 133, doi. 10.1002/eji.201847759
- By:
- Publication type:
- Article
IL13Rα2 expression identifies tissue‐resident IL‐22‐producing PLZF<sup>+</sup> innate T cells in the human liver.
- Published in:
- European Journal of Immunology, 2018, v. 48, n. 8, p. 1329, doi. 10.1002/eji.201747334
- By:
- Publication type:
- Article
Policy responses to hepatitis C in the Nordic countries: Gaps and discrepant reporting in the Hep-Nordic study.
- Published in:
- PLoS ONE, 2018, v. 13, n. 1, p. 1, doi. 10.1371/journal.pone.0190146
- By:
- Publication type:
- Article
Diabetes and Cirrhosis Are Risk Factors for Hepatocellular Carcinoma After Successful Treatment of Chronic Hepatitis C.
- Published in:
- Clinical Infectious Diseases, 2016, v. 63, n. 6, p. 723, doi. 10.1093/cid/ciw362
- By:
- Publication type:
- Article
Functional Attributes of Responding T Cells in HCV Infection: The Recent Advances in Engineering Functional Antiviral T Cells.
- Published in:
- Archivum Immunologiae & Therapiae Experimentalis, 2014, v. 62, n. 1, p. 23, doi. 10.1007/s00005-013-0248-8
- By:
- Publication type:
- Article
A Risk for Hepatocellular Carcinoma Persists Long-term After Sustained Virologic Response in Patients With Hepatitis C–Associated Liver Cirrhosis.
- Published in:
- Clinical Infectious Diseases, 2013, v. 57, n. 2, p. 230, doi. 10.1093/cid/cit234
- By:
- Publication type:
- Article
Cause of death in individuals with chronic HBV and/or HCV infection, a nationwide community-based register study.
- Published in:
- Journal of Viral Hepatitis, 2008, v. 15, n. 7, p. 538, doi. 10.1111/j.1365-2893.2008.00982.x
- By:
- Publication type:
- Article